StockNews.AI
CRNX
StockNews.AI
130 days

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

1. Crinetics will report Q1 2025 results on May 8, 2025. 2. A conference call will follow to discuss financial results and business updates. 3. Crinetics focuses on therapies for endocrine diseases and related tumors. 4. Lead candidate paltusotine targets acromegaly and carcinoid syndrome. 5. Atumelnant is in development for congenital adrenal hyperplasia and Cushing's syndrome.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could reflect positive advancements in drug development and investor interest.

How important is it?

Financial results and updates on developmental candidates can significantly affect stock performance.

Why Short Term?

Market reaction expected soon after Q1 results on May 8; historical reports often influence immediate stock movement.

Related Companies

CRNX
April 11, 2025 08:00 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of www.crinetics.com. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@crinetics.com (858) 345-6075

Related News